Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade

In recent years, there has been considerable interest in mAb-based induction of costimulatory receptor signaling as an approach to combat cancer. However, promising nonclinical data have yet to translate to a meaningful clinical benefit. Inducible T-cell costimulator (ICOS) is a costimulatory recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Yadavilli, Sapna, Waight, Jeremy D., Brett, Sara, Bi, Meixia, Zhang, Tianqian, Liu, Yao-Bin, Ellis, Catherine, Turner, David C., Hahn, Ashleigh, Shi, Hong, Seestaller-Wehr, Laura, Jing, Junping, Xie, Qing, Shaik, Jafar Sadik, Ji, Xiao, Gagnon, Robert, Fieles, William, Hook, Laura, Grant, Steven, Hopley, Stephanie, DeYoung, M. Phillip, Blackwell, Christina, Chisamore, Michael, Biddlecombe, Robert, Figueroa, David J., Hopson, Christopher B., Srinivasan, Roopa, Smothers, James, Maio, Michele, Rischin, Danny, Olive, Daniel, Paul, Elaine, Mayes, Patrick A., Hoos, Axel, Ballas, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430783/
https://www.ncbi.nlm.nih.gov/pubmed/37593752
http://dx.doi.org/10.1158/2767-9764.CRC-22-0293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430783/
https://www.ncbi.nlm.nih.gov/pubmed/37593752
http://dx.doi.org/10.1158/2767-9764.CRC-22-0293

Ejemplares similares